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Abstract: Human pluripotent stem cells (hPSCs) are increasingly gaining attention in 
biomedicine as valuable resources to establish patient-derived cell culture models of the 
cell type known to express the primary pathology. The idea of “a patient in a dish” aims at 
basic, but also clinical, applications with the promise to mimic individual genetic and 
metabolic complexities barely reflected in current invertebrate or vertebrate animal model 
systems. This may particularly be true for the inherited and complex diseases of the retina, 
as this tissue has anatomical and physiological aspects unique to the human eye. For 
example, the complex age-related macular degeneration (AMD), the leading cause of 
blindness in Western societies, can be attributed to a large number of genetic and 
individual factors with so far unclear modes of mutual interaction. Here, we review the 
current status and future prospects of utilizing hPSCs, specifically induced pluripotent stem 
cells (iPSCs), in basic and clinical AMD research, but also in assessing potential treatment 
options. We provide an outline of concepts for disease modelling and summarize ongoing 
and projected clinical trials for stem cell-based therapy in late-stage AMD. 
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1. Introduction 
Age-related macular degeneration (AMD) is the leading cause of severe visual impairment and 
blindness in Western societies. With a steadily increasing life expectancy, the number of people with 
AMD is predicted to further increase worldwide to almost 200 million in 2020 and to over 280 million 
in the year 2040 [1]. Thus far, treatment options are limited and only exist for the neovascular (NV) 
form of late-stage AMD [2,3], a condition characterized by sub-retinal neovascularization with 
detachment of the sensory retina and/or the retinal pigment epithelium (RPE) and hemorrhages 
followed by sub-retinal scarring [4]. Another sight-threatening form of late-stage AMD, known in its 
final manifestation as geographic atrophy (GA), presents as atrophic lesions involving a gradual 
degeneration and disappearance of the RPE and photoreceptor cells within the central retina. The 
proportion of GA versus NV in late-stage AMD is approximately 20%–35% versus 75%–80%. This 
shifts to a higher frequency of GA in the population beyond 85 years of age [5,6] and further 
emphasizes the impact of GA on health in ageing populations. It also underscores the need for an 
effective treatment regimen for the near future. 
AMD is a complex disease with still unknown pathophysiology. Multiple factors have been linked  
to pathogenesis and progression of the disease [7]. Among these are age and smoking, two risk factors 
consistently revealing a strong association with any form of AMD [8–10]. Nutrition, particularly 
dietary antioxidants, reduce AMD risk, as well as the progression of the disease [11–13]. Notably, 
AMD is strongly influenced by genetics. Estimates of heritability, a measure reflecting the proportion 
of observed variation in a particular trait attributable to genetic factors, vary from 45% to  
71% [14–16]. Specifically, genetic variants in the complement pathway have been implicated as a 
major genetic contributor to disease pathology, implying a crucial role of the innate immune system in 
AMD pathogenesis [14,17]. 
AMD pathology relates to the functional syncytium consisting of the neurosensory retina, the RPE 
and the choriocapillaris, including the interjacent extracellular matrix [18], although the primary 
location of initial lesions is suspected to be on the level of the RPE [18,19]. The lack of adequate 
cellular and animal models in AMD has greatly limited our understanding of the molecular 
mechanisms and pathways involved in the development and progression of the disease [20]. Recent 
developments in human pluripotent stem cell (hPSC) research are most promising and could provide 
cellular models eventually mimicking “a patient in a dish”. Indeed, patient-derived cells or tissues are 
as close to the endogenous cellular situation as currently possible. 
Notably, the application of hPSCs has been promoted in the field of ophthalmic research for a 
number of reasons. First, the eye offers easy access to surgical approaches and post-interventional 
follow ups. Furthermore, the cornea provides an excellent window for monitoring disease and 
treatment processes with highly sophisticated non-invasive anatomical and functional tools  
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available [21–23]. Moreover, the eye is less prone to immune rejection of transplanted cells and 
tissues owing to its immune-privileged situation [24], although this privilege might become extinct when 
the blood/retina barrier is compromised due to disease, as is the case in NV AMD [25]. Finally, the 
inherent amplification of signals in the visual system permits noticeable rescue effects on vision given 
a relatively small number of rescued or transplanted cells [26,27]. 
This review discusses the current status and future prospects of utilizing hPSCs for understanding  
the pathomechanisms underlying AMD, but also for its use in assessing potential treatment regimens. 
We give a brief summary of the various types of stem cells available, with a special focus on induced 
pluripotent stem cells (iPSCs). The iPSCs hold particular promises with regard to disease modelling, 
drug screening and cell transplantation therapies of numerous degenerative human diseases [28].  
We describe the generation of iPSCs and their advantages, as well as their limitations. We further 
elucidate the potential and pitfalls of hPSCs for disease modelling of AMD by outlining existing and 
possible concepts. Finally, we highlight some of the ongoing and planed stem cell-based clinical trials 
for AMD. 
2. Stem Cells: Numerous Types, Infinite Potential 
The value of stem cells is highlighted by two distinct properties, specifically the capacity for:  
(i) unlimited self-renewal as a result of asymmetric cell division, where at least one of the daughter 
cells holds traits of stem cells; and (ii) retaining an undifferentiated state and a high potency of cell 
differentiation. The latter feature marks the difference between diverse types of stem cells available in 
the human body. Stem cells can be classified by their differentiation potential: i.e., totipotent stem cells 
can differentiate into both embryonic and extra-embryonic tissue; pluripotent stem cells have the 
ability to form all embryonic tissues (ectoderm, mesoderm and endoderm); and multipotent stem cells 
are able to differentiate into a limited number of somatic cell types, dictated by the degree of the 
earlier differentiation commitment [26,29]. 
Stem cells can also be categorized according to their origin. For example, human embryonic stem 
cells (hESCs) are derived from the undifferentiated inner cell mass of an embryo in the blastocyst  
stage 4–5 days post-fertilization and pre-implantation. The first stable hESC lines in cell culture were 
established by Thompson et al. in 1998 [30]. hESCs proved to be pluripotent with differentiation 
capacities for endoderm, ectoderm, mesoderm and even for germ cells that potentially generate whole 
organisms [30]. These cells promise to be powerful tools for therapeutic purposes, and there are high 
hopes for their use in replacing damaged tissue in patients suffering from degenerative disease [31]. 
However, clinical applications of allogeneic (donor) hESCs still need to overcome limitations and  
safety concerns, such as the restricted efficiency of certain hESC lines to adopt the desired cellular 
phenotypes, genetic and phenotypic instability, risk of graft rejection due to immune response or 
cancer formation after transplantation by residual undifferentiated hESCs [26,31]. Nevertheless, recent 
safety data from the first clinical trials are promising [32]. Moreover, isolating hESCs from the inner 
cell mass inevitably leads to the destruction of the blastocyst, which raises a number of ethical issues 
greatly limiting the broad utilization of hESCs [26,31]. Alternative approaches, specifically for the 
isolation of cells from earlier stages of embryonic development without the necessity to consume the 
embryo, have been addressed. Such approaches have proven successful, but less efficient [33]. 
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Human stem cells can also originate from fetal tissue, such as fetal RPE cells, and are considered 
multipotent [26]. Umbilical cord tissue is another source of multipotent stem cells that have the 
potency to develop into a variety of somatic cell types [26]. Adult stem cells, also known as  
tissue-derived stem cell populations (TSCs), are found in most adult tissues and are able to maintain 
and regenerate a given tissue for a lifetime. Generally, human TSCs (hTSCs) are in a growth-arrested 
state with a slow cell cycle, but can re-enter the cell cycle on demand (e.g., after tissue injury) and give 
rise to differentiating and highly proliferative progenitor cells [26,34]. Importantly, hTSCs are not 
diffusely distributed in adult tissues, but require a stem cell niche, a microenvironment that provides 
external factors necessary for maintaining stem cell properties and functions [26,34]. HTSCs can be 
derived from adult somatic cell sources, suggesting that there might be fewer hurdles to overcome for 
their clinical application. Although endogenous hTSCs may carry fewer risks than allogeneic cell 
transplants, one has to take into account that endogenous hTSCs might often be defective due to 
primary disease; thus, they may not be suitable sources for treating primary disease [34]. A rich supply 
of adult hTSCs is bone tissue, which contains both hematopoietic and mesenchymal stem cells, housed 
in the marrow and the stroma, respectively [26,29,34]. For further information on these special types 
of stem cells, their clinical impact and recently elucidated relationships, the reader is referred to 
Frenette et al., 2013 [35]. Adipose tissue represents an alternative, abundant and easily accessible 
source of adult hTSCs with the ability to differentiate along multiple lineage pathways [36]. 
hTSCs have also been characterized from the adult human eye [37,38]. Well known are the limbal 
epithelial stem cells (LESC’s), which regenerate corneal epithelium throughout life and, thus, have 
potential for clinical applications in corneal diseases [39,40]. With regard to retinal degenerative 
diseases, including AMD, retinal progenitor cells (RPCs) are of particular interest. RPCs have been 
found in the immature human retina, where they represent an immature cell population that is 
responsible for the generation of all retinal neuronal cell types during development, including retinal 
supporter cells, such as the Müller glia [41]. RPCs represent not a uniform type of cells, but rather, a 
group of progenitor cells at different stages of incomplete differentiation. They have also been 
identified in the adult human post-mortem retina by phenotype and neurosphere generation [42]. RPCs 
reveal stem cell-like properties, such as self-renewal abilities in vitro, but with a restricted capacity to 
differentiate into defined retinal neurons [42,43]. Unlike mature photoreceptor cells, RPCs have been 
shown to be reasonably efficient at integrating into the degenerative host retina [27,43]. Likely, their 
further use is limited due to the rather impracticable method of isolation, requiring scarcely available 
fetal or post-mortem tissue. 
In 2006, a novel type of pluripotent stem cells, named induced pluripotent stem cells (iPSCs), 
heralded a major breakthrough in the stem cell field with the expectation to have a significant impact 
on basic science, technology and clinical medicine [29,44,45]. 
3. iPSC: The Stem Cell of the Future? 
iPSCs were initially established from mouse and subsequently from humans [44–46]. Two seminal 
scientific contributions delineated the successful reprogramming of adult human somatic cells into 
pluripotent cells highly resembling hESCs [44,45]. This was achieved by overexpressing four 
transcription factors, including OCT3/4, Sox2, KLF4, c-Myc or OCT4, SOX2, NANOG and LIN28, 
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respectively. Human iPSCs (hiPSCs) exhibit the essential characteristics of hESCs with regard to 
morphology, proliferation, surface antigens, gene expression, epigenetic status of pluripotent  
cell-specific genes and telomerase activity. Furthermore, hiPSCs can differentiate into advanced 
derivatives of all three primary germ layers in vitro and in teratomas. Consequently, these cells can 
differentiate in any somatic cell type of the human body and serve as an unlimited source for defined 
human cells [44,45]. 
Since then, hiPSCs have been appreciated as a valuable cellular source for disease modelling, drug 
screening and cell-based transplantation therapy in human degenerative diseases [29]. Still, critical 
issues need to be addressed, as the detailed mechanisms underlying the reprogramming process during 
hiPSC generation are not well understood at present [47]. 
Overexpression of stem cell factors in adult somatic cells was originally achieved by integrating 
techniques making use of retrovirus [44] or lentivirus [45] vector systems. However, integrating 
vectors have a rather limited clinical application due to potential risks of persistent reactivation of 
intrinsic pluripotency and of genome integration of transgenes. This includes altered differentiation 
potentials of the target cells and insertional mutations, both of which may lead to treatment-associated 
pathologies. Moreover, c-Myc is known as a proto-oncogene, making its clinical use highly unlikely 
due to potential tumor formation [48]. Consequently, techniques were developed to allow the 
generation of transgene-free or integration-free hiPSCs [49]. Those approaches include: (i) the use of 
non-integrating vectors, such as Sendai virus, episomal vectors or minicircle DNA [50–52]; (ii) the 
excision of vectors after integration via the CRE/lox-P system [53]; (iii) DNA-free delivery of factors 
directly as proteins or mRNA [54,55]; and (iv) chemical induction via small molecules [56]. These 
alternatives were shown to be successful, but appear more complex in application [48,49]. 
Of note, the reprogramming efficiency of adult cells to hiPSCs is low and was initially reported 
with a frequency as low as 10−4% [44]. Even to date, further improvements and the use of  
non-integrating approaches do not fundamentally overcome these limitations. Small molecules can 
enhance efficiency and reduce the number of transcription factors required, although increased 
reprogramming frequency and hiPSC safety appear to follow a negative correlation. Clearly,  
large-scale applications of iPSC technology await the validation of sophisticated protocols that 
sufficiently balance these two important elements [48,57]. 
Despite current shortcomings and despite the fact that in vitro cellular models still deviate from 
endogenous in vivo situations, iPSC technology is gaining momentum in the era of personalized 
medicine with the prospect to establish individual, patient-specific cell lines. A rich supply of adult 
donor cells can regularly be obtained from patients by non-invasive techniques. Importantly, in the 
case of autologous transplantation, immune rejection is considered less problematic. By now, various 
sources of somatic cells have been used to generate hiPSCs, among them skin, hair follicle, muscle, 
adipose tissue, bone marrow, peripheral blood lymphocytes and epithelial cells from urine [29,58,59]. 
This raised the issue whether epigenetic marks may persist from the adult cell source in the 
undifferentiated state of the hiPSC. Indeed, bi-sulfite sequencing revealed significant differences in 
methylation patterns between hESCs and hiPSCs and even among different hiPSC lines from the same 
source [29,60,61]. In addition, hiPSCs reveal clonal variation, seem to acquire genomic mutations in 
addition to epigenetic modifications and may have a greater propensity for genomic instability than 
hESCs with a higher rate of point mutations [62,63]. Importantly, these genomic aberrations and point 
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mutations occur despite the exclusion of c-Myc as the reprogramming factor and the use of  
non-integrating methods for transgene delivery [62–64]. Yet, little is known about the causes of these 
mutations, the impact of differences in chromosomal epigenetics and about their biological 
consequences [60,62,65,66]. Another potentially important issue when studying hESCs and hiPSCs as 
models of human diseases are the possible confounding effects of X chromosome inactivation [67–72]. 
Since reprogramming affects the nuclear genome and leaves the mitochondria unaltered, the extent to 
which an aged or altered mitochondrial genome will influence the properties of hiPSCs and their 
derivatives also remains to be evaluated [73]. Genomic instability is recognized as one important 
hurdle in the expanding field of stem cell-based therapies, and growing awareness of the risk factors 
associated with human genome plasticity strongly advocates for the use of extensive genetic 
screenings as a measure of quality control to attest to the safety of stem cell-derived products [74]. 
4. Disease Modelling of AMD: Current Status 
In AMD pathology, the cell types of interest involve the vascular endothelium, the photoreceptors 
and the RPE, all of which are not readily accessible from the patient, but can be generated via hiPSC 
technology: vascular endothelium from hiPSCs was demonstrated to exhibit the rich functional 
phenotypic plasticity of mature primary vascular endothelium [75]. Significant progress was made to 
identify the developmental stimuli that drive hiPSCs differentiation to various neurons, including 
retinal neurons. For example, hiPSCs were differentiated into multi-layer eyecup-like structures with 
the typical features of human retinal precursor cells, including photoreceptor precursors [76]. In 
another study, hiPSC-derived rod photoreceptors exhibited immunocytochemical characteristics and 
electrophysiological properties close to endogenous cells [77]. For further reading on specific aspects 
of hiPSC application to retinal disease, the reader is referred to two excellent reviews by Cramer and 
MacLaren, 2013 [78], and Wright et al., 2014 [79]. Of note, recent work has focused on generating 
retinal ganglion cells from hESCs and hiPSCs [80]. 
As the suspected cellular origin of primary AMD pathology, the RPE has attracted particular 
interest in the field of stem cell differentiation and in vitro modelling. RPE differentiation from hPSCs 
or hiPSCs is straightforward, as this cell type tends to differentiate spontaneously after removal of 
fibroblast growth factor (FGF) from the culture medium [81,82]. The ease of obtaining hiPSC-derived 
RPE cells is advantageous, as degenerative disorders involving the RPE are a common cause of visual 
impairment, highlighting the crucial role of this post-mitotic cell layer in retinal homoeostasis [83,84]. 
Several protocols for the direct differentiation of hPSCs into RPE cells have been established, and RPE 
cell cultures were reported to yield pure populations of functional cells that display many features of 
native RPE. Key parameters are addressed as the four “P’s” (polygonal, pigmented, polarized and 
phagocytic). Specifically, hexagonal cell morphology and pigmentation are pathognomonic for RPE 
cells. Moreover, functional features, such as transepithelial resistance or the polarized secretion 
capacities of known biological factors, like PEDF/VEGF, as well as photoreceptor outer segment 
phagocytosis, are essential characteristics of PRE cells. This is augmented by gene and protein 
expression of mature RPE markers [84–91]. In a note of caution, it was shown that highly 
differentiated, pigmented hiPSC-derived RPE monolayers can undergo only limited serial expansions 
before losing key cytological and functional attributes due to replicative senescence. This again 
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underlines possible confounding effects of passaging cells as a general problem of cell culture disease 
models [88,90]. Addressing the limitation of serial expansion, Croze et al., 2014, found that  
Rho-associated coiled-coil protein kinase (ROCK) inhibition allows for extended expansion of  
hESC-derived RPE cells. These cells remained functional for an enduring, but still finite, period of 
time in culture, possibly mitigating this problem [92]. An important aspect in terms of establishing cell 
repositories is the ability of hiPSC-derived RPE cells to regain viability and function after 
cryopreservation [90]. An exemplary timeline of a hiPSC protocol for generating RPE cells from 
biopsy material of adult skin is summarized in Figure 1. The reader is further referred to a 
sophisticated review by Bharti et al., 2011. The authors emphasize the absolute necessity of providing 
an operational definition of a true RPE cell and offer a detailed list of testable criteria to monitor the 
molecular and functional authenticity of stem cell-derived RPE cells [91]. 
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Figure 1. Representative timeline for the generation of skin biopsy-derived hiPSCs (a) and 
differentiated RPE cells (b). Major steps in the process are summarized. To obtain hiPSCs, 
integrating polycistronic lentiviral transduction via spinfection has been applied [90]. Due 
to the progress in the field of stem cell research, a number of integrating, but also  
non-integrating, protocols are available, and other sources than fibroblasts, such as blood 
lymphocytes, are widely used [29]. 
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The validity of a hiPSC-derived RPE cell culture model greatly depends on its ability to mimic the 
behavior of native RPE cells in responding to normal and disease-associated stimuli. Consequently, 
hiPSC-derived RPE cells should reveal a set of expressed genes comparable to pure native RPE cells.  
A comparison of genome-wide expression profiles may provide a sensitive approach elucidating the 
differences and similarities in overall gene expression of two RPE lines. For example, by RNA 
sequencing, we compared a number of RPE lines, including hiPSC-derived RPE cells, an established 
RPE cell line, ARPE19 [93], native RPE/choroid tissue and retinal tissue. In addition, we analyzed the 
cell lineages used to generate the hiPSC-derived RPE, such as the dermal fibroblast cells and the 
hiPSCs generated thereof. The RNA reads obtained were aligned to reference sequences and quantified 
with tuxedo suite tools [94,95]. Principal component analysis grouped different cell types (and their 
replicates) according to their expression profile. This algorithm searches for genes with the highest rate 
of variation across all samples and groups the samples according to these genes. Our data reveal that 
independent cell lines and tissues from different donors have an overall high similarity in  
genome-wide gene expression (Figure 2a,b). Interestingly, native RPE tissue exhibits significant 
differences between its biological replicates (Figure 2a), which could be due to variation in the 
methods of tissue collection, post-mortem status or the variable degree of “contamination” of RPE 
with choroid or retinal tissue. This underlines that collecting native RPE tissue has numerous pitfalls 
and limitations for further (clinical) applications. Of interest, our data demonstrate a high similarity of 
hiPSC-derived RPE to native human RPE tissue, again underscoring the validity of hiPSC-derived 
cellular RPE models (Figure 2a,b). 
A pathway enrichment analysis on differentially expressed genes points to those genes and 
pathways that mainly distinguish between the various cell types analyzed. To this end, two hundred 
genes with the highest variation between two different cell types/tissues were selected, analyzed with 
G:profiler software, and significantly enriched KEGG (Kyoto Encyclopedia of Genes and Genomes) 
pathways were recorded (corrected p-value <0.05). This demonstrates that genes with strong 
expression differences between iPSC-RPE cells and native RPE tissue are associated with only two 
pathways: mineral absorption (KEGG:04978) and general metabolism pathways (KEGG:01230, 
KEGG:00010, KEGG:01200, KEGG:00270) (Figure 3). In contrast, ARPE19 cells showed clear 
differences in several pathways to both native RPE tissue and iPSC-derived RPE cells. Together, these 
data show that hiPSC-derived RPE cells provide a cell culture model well in line with the native 
situation, not only morphologically and metabolically, but also in its global expression profile. 
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Figure 2. Deep RNA-sequencing and principal component analysis of different cell lines 
and tissues. (a,b) Deep RNA sequencing to analyze global gene expression profiles was 
performed for biological replicates of hiPSC-RPE cells, native RPE tissue, ARPE19 cells, 
RPE/choroid tissue, retinal tissue, hiPSCs and fibroblasts. Samples were clustered 
according to the main Components 2, 3 and 4. Results of the principal component (PC) 
analysis are given as (a) a 3D plot and (b) a phylogenetic tree. Comparison of global gene 
expression underlines the resemblance of hiPSC-RPE cells to native RPE tissue and 
indicates differences among native RPE tissue samples. 
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Figure 3. Kyoto Encyclopedia of Genes and Genomes (KEGG)-pathway analysis of 
different cell lines and tissues. Two hundred genes revealing the highest variances in  
RNA-Seq testing were selected and subjected to pathway enrichment analysis in the 
“G:Profiler” Software. Different colors code for different pathways. Broader lines indicate 
a lower p-value obtained from the pathway enrichment analysis. 
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5. Disease Modelling of AMD: Future Possibilities 
A recent study by Chang et al. [82] demonstrated that hiPSC-derived RPE cells from patients with 
GA due to AMD have a decreased antioxidative defense, making these cells susceptible to oxidative 
damage. Subsequently, curcumin, a potent ingredient of the spice plant, Curcuma longa, protected 
these cells from H2O2-induced cell death and also increased the cytoprotective effects against the 
induced oxidative stress. Notably, curcumin modulated the expression of several oxidative  
stress-regulating genes, which led the authors to conclude that this substance could be used as a drug 
effectively restoring RPE function [96]. This proof-of-concept study expertly illustrated the potential 
use of iPSC technology in future efforts to understand and treat AMD. 
In combination with novel technologies to manipulate cell lines within a defined genetic 
background, such as CRISP/Cas9 editing of the genome [97], functional consequences of a single 
variant on the cellular phenotype can be delineated within a complex network of genetic risk and  
non-risk factors. In this context, it is of note that a complex late onset disorder, such as AMD, likely 
expresses a chronic low level pathology that is possibly influenced by differences in genetic 
background in addition to sequence variations in the disease-associated genes [98]. This makes it 
problematic when comparing hiPSC-derived RPE cells from a healthy control versus an affected 
individual, even when derived from siblings. Gene editing on a well-defined genetic background, e.g., 
via CRISPR/Cas9 editing [27,97], appears to be the method of choice and ideally allows assessing 
single AMD-associated sequence variants on a defined (high or low risk) isogenic background. 
Functionally, the hiPSC-derived RPE cell lines from AMD patients can be analyzed in a great 
variety of cellular studies. Importantly, these studies can include responses of the RPE cells to 
challenges, including natural chronic stressors mimicking environmental risk factors associated with 
AMD, such as short-term and long-term photoreceptor outer segment (POS) feeding [99], activation of 
the complement cascade via human sera [17] or cigarette smoke simulated by cigarette extracts and 
nicotine [9,100,101]. Of note, Cano et al. expertly reviewed how cigarette smoke and oxidative stress 
to the RPE might contribute to AMD [102]. High throughput “omics” approaches to generate  
genome-wide transcriptome or metabolome profiles of AMD patient-derived hiPSC-RPE cells could 
help to define pathways in AMD pathogenesis. In turn, this could further our understanding of the 
consequences of a defined genetic variant and may elucidate local molecular mechanisms contributing 
to AMD pathology. 
As mentioned previously, AMD pathology involves not only the RPE, but also immediately 
associated structures, such as the vascular endothelium and the photoreceptors. Therefore, it is 
tempting to consider future complex in vitro models that could include the RPE, human Bruch’s 
membrane (BM) and the subjacent choriocapillaris. This would allow expanding analysis from cells 
with simply having pathologic genetic alterations to investigate pathophysiological cellular interactions 
between the different cells types involved. Several models for co-culturing RPE with, e.g., endothelial 
cells have been described and may specifically be useful for studying NV AMD [103]. 
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6. Cell-Based Therapy in AMD: Current and Projected Clinical Trials 
Therapeutic applications of stem cells can be based on different strategies. For cell replacement 
therapy, stem cells are differentiated into the desired somatic cell type, which is then delivered to the 
diseased tissue in order to integrate and restore function [26]. An alternative approach uses the 
paracrine effect of transplanted stem cells, which secrete trophic factors that induce the resident tissue to 
self-restore and proliferate [26,104]. Additionally, there is some evidence that stem cells may fuse with 
individual existing cells in order to restore cellular function [26,104,105]. 
The focus in retinal stem cell-based therapy has been on replacement of photoreceptors and RPE. 
Substituting an RPE monolayer beneath the retina appears less complex than replacing retinal neurons, 
which need to integrate into the retinal network to ensure functionality [26]. Accumulating studies in 
animal models of retinal degeneration showed promising results [79], and in 2012, the first therapeutic 
stem cell application in a human clinical trial was reported by Schwartz et al. [106] with safe  
sub-retinal injections of hESC-derived RPE cells into patients with Stargardt disease and GA due to 
AMD. In a recent follow-up study including 18 participants, this group has again reported the safety of 
this therapeutic approach. In addition, the authors have also demonstrated improved vision in four out 
of nine AMD patients treated [32]. Interestingly, only few, if any, pigmented transplanted RPE single 
cells survived in the direct area of GA lesions. Instead, transplanted cells were detectable in areas 
adjacent to areas of GA, where they were deposited onto native RPE. Organ culture experiments also 
underline that aged and thickened submacular human Bruch’s membrane (BM) does not support  
long-term survival and differentiation of transplanted RPE [107,108]. Thus, if RPE transplants are 
meant to preserve and rescue high-acuity vision, developing strategies to improve transplanted RPE 
cell survival in areas of GA, typically adjacent to the fovea, will be crucial. Importantly, this implies 
that therapeutic application of stem cell technology for AMD may require not only development of the 
appropriate mature cell type, but also management of the extracellular milieu. Clinical cell-based 
transplantation trials have tried to overcome these hurdles by using RPE sheets instead of cell 
suspensions of disorganized RPE single cells [109,110]. RPE sheets can be grown on artificial 
scaffolds, which appear suited to replace the diseased BM [109]. On the downside, these techniques 
require a more complex surgical procedure; biodegradable materials might cause inflammation; while 
non-degradable membranes may separate the RPE from the underlying choroid that nourishes RPE and 
photoreceptors [110]. Table 1A,B provides an overview of current and projected clinical trials 
involving cell-based therapeutic approaches for late-stage AMD and summarises the main aspects of 
these studies. For more detailed information, references are provided. 
HiPSC-derived RPE cells could emerge as valuable tools to explore potential treatment regimens. 
Proof-of-concept studies exist [96], but future concepts may want to emphasize molecular and 
functional differences between hiPSC-derived RPE cells from patients with low or high genetic risk 
for developing AMD. These differences could be targeted via large-scale drug screening experiments 
with a genotype-specific platform to define appropriate readouts. This could prove helpful in clinical 
trials to further promote personalized medicine in this blinding disorder. 
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Table 1. Phase I/II prospective safety (and efficacy) studies for stem cell-based therapy of late-stage AMD. (A) Integrating cell replacement 
strategies to engraft long-term and/or to functionally replace the degenerated endogenous RPE; (B) Non-integrating cell injections that 
mediate the effects by homing/modulating the inflammatory environment and/or releasing neuroprotective cytokines. 
Study Centre 
Year of 
Launch/Status 
(Stem) Cell  
Type Used 
Main Facts 
Publications/Sources  
(NCT = ClinicalTrials.gov 
Identifier) 
A 
Jules Stein Eye Institute at 
University of California Los 
Angeles (UCLA), USA; 
Advanced Cell Technology, 
Inc., Marlborough, 
Massachusetts, MA, USA  
2011/preliminary 
report published  
in 2012 
hESC-derived 
RPE suspension 
 sub-macular injection via vitrectomy in one patient with Stargardt macular 
dystrophy and one patient with atrophic AMD 
 hESC-derived RPE cells persisted for four months; no signs of 
hyperproliferation, tumorigenicity, ectopic tissue formation or apparent rejection 
 vision improvement in patient with atrophic AMD from 21 Early Treatment 
Diabetic Retinopathy Study (ETDRS) letters to 28 
Schwartz et al., 2012 [106]; 
NCT01345006; 
NCT01344993 
Multi center USA (Jules Stein 
Eye Institute at UCLA, Los 
Angeles, LA, USA; Bascom 
Palmer Eye Institute, Miami, 
FL, USA; Wills Eye  
Institute-Mid Atlantic Retina, 
Philadelphia, PA, USA; Mass 
Eye and Ear, Boston, USA); 
Advanced Cell Technology, 
Inc., Marlborough, 
Massachusetts, MA, USA  
2011/report 
published in 2014 
hESC-derived 
RPE suspension 
 sub-macular injection via vitrectomy in patients with advanced Stargardt macular 
dystrophy and atrophic AMD 
 enrolment of 18 patients in four study centers in the USA 
 extension of the study above 
 follow-up period for a median of 22 months 
 no evidence of adverse proliferation, rejection or serious ocular or systemic 
safety issues 
 increase in subretinal pigmentation consistent with transplanted RPE cells in 13 
of 18 patients 
 improvement in visual acuity of at least 15 ETDRS letters in eight of 18 patients 
 increased vision-related quality-of-life measures 
Schwartz et al., 2014 [32]; 
NCT01345006; 
NCT01344993 
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Table 1. Cont. 
Study Centre 
Year of 
Launch/Status 
(Stem) Cell  
Type Used 
Main Facts 
Publications/Sources  
(NCT = ClinicalTrials.gov 
Identifier) 
University College London, 
Moorfields Eye Hospital, 
London, U.K.;  
Pfizer, Walton Oaks, U.K. 
2007/stem cell 
transplantation  
trial approved in 
2013, ongoing 
hESC-derived 
RPE sheets 
 transplantation of thin sheets of plastic polymer via vitrectomy in patients with 
neovascular AMD 
 goal to overcome disadvantages of cell suspension 
 currently preparing the transplantation cells/sheets in vitro 
Carr et al., 2013 [109]; 
NCT01691261  
Riken Institute, Kobe, Japan 2013/ongoing 
autologous 
hiPSC-derived 
RPE sheets 
 sub-macular transplantation to neovascular AMD patients after surgical removal 
of choroidal neovascularisation (CNV) 
 GMP-grade cell-processing facility 
 pilot safety study, enrolment of six patients (estimated), follow-up for three years
 Nakano-Okuno et al., 2014 [111], describe risk-benefit analysis 
Kamao et al., 2014 [110]  
B 
Hollywood Eye Institute, 
Cooper City, Florida, FL, USA;
Bioheart, Inc., Sunrise, Florida, 
FL, USA 
2013/completion 
2016 (estimated) 
autologous 
adipose-derived 
stem cells (ASCs)
 intravitreal injection in atrophic AMD patients 
 ASCs derived via liposuction; primary outcome measures: adverse events, visual 
acuity, visual field analysis 
NCT02024269 
University of California; 
Davis Eye Center, Sacramento, 
California, CA, USA 
2012/completion 
2014 (estimated) 
autologous 
CD34+ bone 
marrow stem 
cells (BMSCs) 
 Intravitreal injection in retinal degenerative conditions (atrophic AMD, retinitis 
pigmentosa) or retinal vascular disease (diabetes, vein occlusion); primary 
outcome measures: adverse events 
Park et al., 2012 [112]; 
NCT01736059 
Multi center USA;  
Stem Cells, Inc., Newark, 
California, CA, USA 
2012/completion 
2015 (estimated) 
human central 
nervous system 
stem cells 
(HuCNS-SC) 
 unilateral transplantation into sub-retinal space through standard surgical 
approach in patients with advanced atrophic AMD; primary outcome measures: 
adverse events 
McGill et al., 2012 [113]; 
NCT01632527 
Rubens Siqueira Research 
Centre, São Paulo, Brazil; 
University of Sao Paulo, São 
Paulo, Brazil 
2011/completion 
January, 2014 
(estimated) 
autologous 
BMSC 
 intravitreal injection in patients with advanced AMD (atrophic or neovascular); 
primary outcome measures: change in visual acuity 
Siqueira et al., 2011 [114]; 
NCT01518127 
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7. Conclusions 
Retinal degenerative diseases, in particular highly prevalent diseases, such as AMD, with a high risk 
of losing vision, claim a tremendous societal burden in terms of quality of life, decrease in productivity 
and healthcare expenditures [79]. Consequently, there is an urgent medical need to advance strategies 
for understanding their pathophysiologies and for establishing valid platforms for rapid therapeutic 
developments. Stem cell-based disease modelling is a novel and rapidly advancing field with 
apparently unlimited potential to meet those demands. A number of proof-of-concept studies have 
been published and have further underscored the advancements and the power of stem cell  
technology [47,79,115], heralding a new era in biomedical research, as well as drug discovery  
and development. 
Of particular interest are the opportunities in the field of personalized medicine. Patient-derived 
hiPSCs and their tissue-specific derivatives may be used to individually identify and test drugs for their 
effectiveness in a complex genetic environment. Furthermore, stem cell-based replacement therapies 
could be tailored to the patients’ needs, although the immunological advantageous of autologous cell 
transplantation may be lost unless the harmful genetic constellation of the donor’s cells can be 
corrected. GMP-grade cells for transplantation are available, and the first clinical applications for RPE 
cell replacement are under way [110]. Based on these visionary developments, which build upon major 
technical innovations in stem cell research, we trust to see light at the end of the tunnel in the  
near future. 
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